Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment

作者全名："Jing, Weihong; Jiang, Mingyue; Fu, Xiaoxue; Yang, Jiaxin; Chen, Lu; Leng, Feng; Xu, Ping; Huang, Wenyan; Yu, Chao; Yang, Zhangyou"

作者地址："[Jing, Weihong; Jiang, Mingyue; Fu, Xiaoxue; Yang, Jiaxin; Chen, Lu; Leng, Feng; Xu, Ping; Huang, Wenyan; Yu, Chao; Yang, Zhangyou] Chongqing Med Univ, Coll Pharm, Chongqing Pharmacodynam Evaluat Engn Technol Res C, Chongqing Key Lab Pharmaceut Metab Res, Chongqing 400016, Peoples R China"

通信作者："Yu, C; Yang, ZY (通讯作者)，Chongqing Med Univ, Coll Pharm, Chongqing Pharmacodynam Evaluat Engn Technol Res C, Chongqing Key Lab Pharmaceut Metab Res, Chongqing 400016, Peoples R China."

来源：INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:000851014600001

JCR分区：Q1

影响因子：8.2

年份：2022

卷号：214

期号：　

开始页：697

结束页：707

文献类型：Article

关键词：Self-assembly; Obesity; Nonalcoholic fatty liver disease; BAM15; Drug -albumin nanocomposites

摘要："Nonalcoholic fatty liver disease (NAFLD) is a chronic metabolic liver disease closely related to obesity, which has become a global health problem. However, current pharmacological therapies for NAFLD are limited by potential side effects, low effectiveness and poor aqueous solubility. Herein, we designed functionalized drug-albumin nanocomposites (BAM15@BSA NPs), which were prepared by self-assembly of the anti-obesity small-molecule drug (BAM15) and bovine serum albumin (BSA), for treatment of NAFLD. The proposed BAM15@BSA NPs not only improve aqueous solubility and half-life of BAM15 but also exhibit hepatic-targeted capacity and an increased therapeutic efficacy. In vitro experiments revealed that BAM15@BSA NPs possessed excellent biocompatibility, and improved resistance to adipogenesis and reduced lipid accumulation in human hepatocellular carcinoma cells. In vivo, BAM15@BSA NPs showed liver targeting ability and powerful anti-obesity effects without altering body temperature or affecting food intake, and could effectively alleviate hepatic steatosis and improve therapeutic efficacy for NAFLD treatment. The above findings demonstrated that BAM15@BSA NPs potentially served as a safe and effective drug for NAFLD treatment."

基金机构："Youth Talent Foundation in College of Pharmacy, Chongqing Medical University [YXY2019QNGD1]; Natural Science Foundation of Chongqing [cstc2021jcyj-msxmX0246]"

基金资助正文："Acknowledgments W. H. Jing and M. Y. Jiang contributed equally to this work. This work was financially supported by Youth Talent Foundation in College of Pharmacy, Chongqing Medical University (No. YXY2019QNGD1) , and Natural Science Foundation of Chongqing (cstc2021jcyj-msxmX0246) ."